Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000817248 | SCV000957798 | pathogenic | Neonatal encephalomyopathy-cardiomyopathy-respiratory distress syndrome | 2023-04-10 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. ClinVar contains an entry for this variant (Variation ID: 660116). Disruption of this splice site has been observed in individuals with primary coenzyme Q10 deficiency (PMID: 31396399). It has also been observed to segregate with disease in related individuals. This variant is present in population databases (rs747779231, gnomAD 0.03%). This sequence change affects a donor splice site in intron 4 of the COQ4 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in COQ4 are known to be pathogenic (PMID: 25658047). |
Revvity Omics, |
RCV000817248 | SCV002023372 | likely pathogenic | Neonatal encephalomyopathy-cardiomyopathy-respiratory distress syndrome | 2020-03-23 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV003480866 | SCV004227139 | pathogenic | not provided | 2023-05-15 | criteria provided, single submitter | clinical testing | PM2, PS1, PVS1 |